Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. Mai 2025 08:00 ET | Quelle: Alzamend Neuro, Inc.

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Mass. General Hospital
13. Mai 2025 08:00 ET | Quelle: Alzamend Neuro, Inc.

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Mass. General Hospital; Topline Data by Year-End
07. Mai 2025 08:00 ET | Quelle: Alzamend Neuro, Inc.

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for Its Phase II Clinical Trial of AL001 Study to Take Place at Mass. General Hospital
11. März 2025 08:00 ET | Quelle: Alzamend Neuro, Inc.

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for AL001 Treatment of Post-Traumatic Stress Disorder at Massachusetts General Hospital